As Asia Gets Richer, Singapore's EDB Turns Investments To Tech-enabled, Remote Monitoring Start-Ups
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - The Singaporean government's leading investments arm, EDB Investments, is increasingly betting on small-sized companies that leverage advanced communication technologies like mobile phones or remote monitoring to develop healthcare solutions
You may also be interested in...
Singapore’s Dx Assay Pushing Fee-for-service Model In Companion Diagnostics
Dx assays Pte. Ltd. says its fee-for-service business model makes it a unique provider of companion diagnostics in a market set to boom globally as U.S. FDA and other regulators push for drug firms to develop diagnostics alongside drugs.
Singapore’s Bio*One Capital Eyes Services, Data and Devices In Investment Push: An Interview With PharmAsia News
The biomedical investment arm of Singapore’s state-run investment firm EDBI, gives PharmAsia News insight into where its next round of investments are aimed.
Asia Innovators: Singapore's Inviragen In Race With Sinovac For HFMD Vaccine
SINGAPORE - Inviragen (Singapore) Pte Ltd is recruiting patients for its Phase I clinical trial in Singapore for its hand, foot and mouth disease vaccine INV21